(Circulation. 1997;95:240-244.)
© 1997 American Heart Association, Inc.
Articles |
Vascular Endothelin-1 Gene Expression and Effect on Blood Pressure of Chronic ETA Endothelin Receptor Antagonism After Nitric Oxide Synthase Inhibition With L-NAME in Normal Rats
the MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal (Quebec), Canada.
Correspondence to Ernesto L. Schiffrin, MD, PhD, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7.
Background Vascular expression of the endothelin-1 gene may be associated with severe vascular hypertrophy. Because in rats, inhibition of NO synthase with the L-arginine analogue N
-nitro-L-arginine methyl ester (L-NAME) induces blood pressure elevation associated with little cardiovascular hypertrophy, we studied vascular endothelin-1 gene expression in L-NAME–treated rats and the effects of chronic endothelin antagonism.
Methods and Results Sprague-Dawley rats received 100 mg·kg-1·d-1 L-NAME in their drinking water for 3 weeks. Systolic blood pressure rose to 189±3 mm Hg (P<.001 versus control rats). By Northern blot analysis, endothelin-1 mRNA levels were similar in aortas and mesenteric arteries of control and L-NAME–treated rats. The blood pressure of L-NAME hypertensive rats treated with the ETA-selective endothelin receptor antagonist A-127722 for 3 weeks at a low dose (10 mg·kg-1·d-1) and a high dose (30 mg·kg-1·d-1) was not different from that of rats receiving L-NAME but not the endothelin antagonist. Treatment with the ACE inhibitor cilazapril lowered the blood pressure of L-NAME–treated rats equally whether or not they were receiving the ETA antagonist.
Conclusions These results indicate that the endothelin system does not participate to an important degree in the mechanisms leading to elevated blood pressure after chronic NO synthase inhibition with L-NAME in normal rats. In the chronic model of L-NAME–induced hypertension, blockade of the renin-angiotensin system does not unmask an endothelin-dependent vasopressor tone. In addition, either NO does not regulate vascular endothelin-1 gene expression or L-NAME exerts an inhibitory effect on endothelin expression in blood vessels.
Key Words: hypertension • arteries • hypertrophy • angiotensin
This article has been cited by other articles:
 |
|
 |
|
  F. Vargas, J. M. Moreno, R. Wangensteen, I. Rodriguez-Gomez, and J. Garcia-Estan The endocrine system in chronic nitric oxide deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cardillo, C. M. Kilcoyne, R. O. Cannon III, and J. A. Panza Increased activity of endogenous endothelin in patients with hypercholesterolemia J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1483 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Reinhart, L. C. Preusser, T. J. Opgenorth, C. D. Wegner, and B. F. Cox Endothelin and ETA receptors in long-term arterial pressure homeostasis in conscious nonhuman primates Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2000; 279(5): R1701 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-m. Gan, L. Selin-Sjogren, R. Doroudi, and S. Jern Temporal regulation of endothelial ET-1 and eNOS expression in intact human conduit vessels exposed to different intraluminal pressure levels at physiological shear stress Cardiovasc Res, October 1, 2000; 48(1): 168 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. H. Schiffers, D. Henrion, C. M. Boulanger, E. Colucci-Guyon, F. Langa-Vuves, H. van Essen, G. E. Fazzi, B. I. Levy, and J. G. R. De Mey Altered Flow-Induced Arterial Remodeling in Vimentin-Deficient Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Schiffrin Role of Endothelin-1 in Hypertension Hypertension, October 1, 1999; 34(4): 876 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Jeremy, D. Rowe, A. M. Emsley, and A. C. Newby Nitric oxide and the proliferation of vascular smooth muscle cells Cardiovasc Res, August 15, 1999; 43(3): 580 - 594. [Full Text] [PDF]
|
|
|
|
|
|
H. Berthold, K. Munter, A. Just, H. R. Kirchheim, and H. Ehmke Stimulation of the Renin-Angiotensin System by Endothelin Subtype A Receptor Blockade in Conscious Dogs Hypertension, June 1, 1999; 33(6): 1420 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Tharaux, C. Chatziantoniou, D. Casellas, L. Fouassier, R. Ardaillou, and J.-C. Dussaule Vascular Endothelin-1 Gene Expression and Synthesis and Effect on Renal Type I Collagen Synthesis and Nephroangiosclerosis During Nitric Oxide Synthase Inhibition in Rats Circulation, April 27, 1999; 99(16): 2185 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, S. Colonna, E. Pavan, G. Albertin, F. Della Rocca, G. Gerosa, D. Casarotto, S. Sartore, P. Pauletto, and A. C. Pessina Endothelin-1 and Its mRNA in the Wall Layers of Human Arteries Ex Vivo Circulation, March 9, 1999; 99(9): 1147 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. M. Avontuur, F. Boomsma, A. H. van den Meiracker, F. H. de Jong, and H. A. Bruining Endothelin-1 and Blood Pressure After Inhibition of Nitric Oxide Synthesis in Human Septic Shock Circulation, January 19, 1999; 99(2): 271 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zatz and C. Baylis Chronic Nitric Oxide Inhibition Model Six Years On Hypertension, December 1, 1998; 32(6): 958 - 964. [Full Text] [PDF]
|
|
|
|
|
|
P. Moreau Endothelin in hypertension: A role for receptor antagonists? Cardiovasc Res, September 1, 1998; 39(3): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Smith, J. D. Smith, and D. S. Criswell Involvement of nitric oxide synthase in skeletal muscle adaptation to chronic overload J Appl Physiol, May 1, 2002; 92(5): 2005 - 2011. [Abstract] [Full Text] [PDF]
|
|